Neuphoria Therapeutics Inc. (NEUP) stock
NEUPNasdaqPharmaceutical PreparationsFiscal year ends June 30
$2.55−0.03 (-1.16%)
Close on Nov 13, 2026Market cap $76.66KP/E –Yield –
Neuphoria Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Neuphoria Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$12.35M, down 16095.4% year over year. For fiscal 2026 it was -$12.35M, down 16095.4% from the year before.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | -$12.35M | -16095.4% |
| FY2025 | Jun 30, 2025 | $77.23K | – |
| FY2024 | Jun 30, 2024 | -$14.68M | – |
| FY2023 | Jun 30, 2023 | -$14.64M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | $1.21M | – |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | -$3.34M | -129.1% |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | -$6.44M | – |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | -$3.79M | – |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | -$3.59M | – |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | $11.45M | – |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | -$3.36M | – |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | -$4.43M | – |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | -$3.01M | – |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | -$3.30M | – |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | -$3.95M | – |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | -$4.43M | – |
See a number that looks wrong?